The global Head and Neck Cancer Drugs/Therapeutics Market was valued at USD 752.5 million in 2016 and is estimated to grow significantly in the coming years owing to the development of cost-effective and innovative Head and Neck Cancer treatments. Cancers of squamous cells present in the linings of the larynx, nose, salivary glands, throat, lips, and mouth cause Head and Neck Cancers. Head and Neck Cancer is amongst the common type of cancers. The records reveal that every year a massive number of Head and Neck Cancers are detected globally with more than half accounting for death annually. The increasing number of Head and Neck Cancer patients and the demand for cost-efficient treatment options are helping the Head and Neck Cancer Drugs/Therapeutics Market to grow with a CAGR of 9.4%.
The most preferred therapy performed by the surgeons is surgical therapy combined with radiation therapy. Moreover, the present treatment options available for Head and Neck Cancer results in less chances of survival rate. The latest developments in advanced radiotherapy and chemotherapy have helped to preserve some functions of the face. The treatment for Head and Neck Cancer is a significant challenge for the surgeons since the choice of treatment differs from patient to patient and tumor location. Generally, the Head and Neck Cancers are operated on with the surgery, but the complicated facial structures and functions restrict the surgical operations. However, more focus is now being given to the technological developments of new targeted molecules like gene therapy, antibody-drug conjugates, monoclonal antibodies, etc. This is expected to widen the market opportunities in near future, which will fuel up the market growth.
The market is categorized on the grounds of treatment type, disease indication, end-user, and geography. On the grounds of treatment type, the market is distributed into Chemotherapy, Radiation Therapy, External Radiation Therapy, Internal Radiation Therapy, Surgery, and Targeted Therapy. Surgery, bringing the most preferred therapy choice is projected to lead the Head and Neck Cancer Drugs/Therapeutics Market in the forecast period. To prevent the reoccurrence of cancer, Radiation therapy is used which is expected to contribute largely to the market after the surgery. Furthermore, Chemotherapy is an assistant treatment to other therapies and therefore is expected to contribute the little share in the Head and Neck Cancer Drugs/Therapeutics Market.
On the grounds of disease indication, the market is distributed into Laryngeal Cancer, Lip and Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, etc. Lip and Oral Cavity cancer is predicted to rise globally due to the growing number of people affected by lip and oral cancer. On the grounds of end-user, the Head and Neck Cancer Drugs/Therapeutics Market is distributed into Hospitals, Specialty Clinics, and Ambulatory Surgical Centers. Hospital is expected to contribute a comparatively larger share.
Geographically, the market is segmented as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. The Head and Neck Cancer Drugs/Therapeutics Market share from North America will continue to dominate due to the high prevalence high smoking rate and HPV-induced cancers. After this, Europe is expected to contribute the second largest market share. The leading players in the Head and Neck Cancer Drugs/Therapeutics Industry are profiled as Merck & Co. Eli Lilly, Merck Group and Bristol-Myers Squibb, Sanofi.
Head and Neck Cancer Drugs Therapeutic Class Outlook (Revenue, USD Million, 2016 - 2022)
• PD Inhibitors
• EGFR Inhibitors
• Microtubule Inhibitors
Head and Neck Cancer Drugs Regional Outlook (Revenue, USD Million, 2016 - 2022)
• the U.S.
• the U.K.
Research Support Specialist, USA
FREE sample contains market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...